HAEMOSTATIX
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients.
HAEMOSTATIX
Industry:
Biotechnology Clinical Trials Health Care Medical
Founded:
2003-01-01
Address:
Nottingham, Nottingham, United Kingdom
Country:
United Kingdom
Website Url:
http://www.haemostatix.com
Total Employee:
11+
Status:
Active
Contact:
+4401159124512
Total Funding:
6.98 M USD
Technology used in webpage:
SPF Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET Ajax Namecheap DNS
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Praxis Precision Medicines
Praxis Precision Medicines offers drug development services.
Current Employees Featured
Founder
Investors List
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Spark Ventures
Spark Ventures investment in Venture Round - Haemostatix
Catapult Ventures
Catapult Ventures investment in Venture Round - Haemostatix
Nesta Ventures
Nesta Ventures investment in Venture Round - Haemostatix
Wellcome Trust
Wellcome Trust investment in Venture Round - Haemostatix
Esperante Ventures
Esperante Ventures investment in Venture Round - Haemostatix
Spark Ventures
Spark Ventures investment in Series C - Haemostatix
Esperante Ventures
Esperante Ventures investment in Series C - Haemostatix
Official Site Inspections
http://www.haemostatix.com
- Host name: 185-151-30-164.ptr4.stackcp.net
- IP address: 185.151.30.164
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
